Insulin Cancer Research Results

Insulin, Insulin: Click to Expand ⟱
Source:
Type:
Insulin, traditionally known for its role in regulating blood glucose levels, also exerts potent mitogenic (cell division–promoting) effects.

Insulin exerts its effects primarily through binding to the insulin receptor (IR), a receptor tyrosine kinase. Upon binding, the receptor undergoes autophosphorylation and activates several downstream signaling cascades, including:
-PI3K/Akt Pathway: Overactivation of this pathway is often observed in cancers.
-RAS/MAPK Pathway: aberrant activation can lead to tumorigenesis.

IR-A: Often predominates in fetal tissues and some cancer cells. It has a higher affinity for insulin-like growth factors (IGFs) and is more mitogenic.
IR-B: More involved in metabolic regulation.

Studies have shown that many cancers (such as breast, colon, and lung cancers) preferentially overexpress the IR-A isoform.
Scientific Papers found: Click to Expand⟱
7638- Ins,    d-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI)
- Review, Nor, NA
*Insulin↝, d-Chiro-inositol acts through a variety of mechanisms, acting as an insulin sensitizer, inhibiting the transcription of aromatase, in addition to modulating white adipose tissue/brown adipose tissue transdifferentiation.
*CYP19↓,
*Dose↝, Unlike myo-Ins, which is readily available through the diet, primarily in corns, beans, fruits, and nuts [8], it is near impossible to consume sufficient d-chiro-Ins as only a few foods (e.g., buck wheat, soy-lecithin, carob, and lentils) contain sig
*Dose↝, Therefore, d-chiro-Ins is mainly synthesized in the body from myo-Ins
*other↝, ratio between myo-Ins and d-chiro-Ins:. In the plasma, the ratio is 40:1, while in energy-dependent tissues, such as fat or liver, this drops to 2:1. tissue types that have a highglucose consumption rate, such as the brain, display a ratio of 200:1
*Insulin↓, The combined actions of the above mechanisms result in a reduced insulin requirement, thus decreasing systemic insulin levels
*IRes↓, inositol supplementation has shown great success in counteracting IR in a variety of conditions
*Obesity↓, reported a significant reduction in BMI in patients under 30 years of age and PCOS women, suggesting that inositol may have potential as an adjunct therapy to obesity care
*BioAv↝, In a minority of patients, myo-Ins has been observed to have poor bioavailability and efficacy, leading to the phenomenon of “inositol resistance,” which is associated with patients who are unresponsive to myo-Ins supplementation.


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

IRes↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↓, 1,   Insulin↝, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CYP19↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   Dose↝, 2,  

Functional Outcomes(tgid=23) ⓘ

Obesity↓, 1,  
Total Targets: 8

Scientific Paper Hit Count for: Insulin, Insulin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1190  State#:%  Dir#:4
  wNotes=on  sortOrder:rid,rpid

 

Home Page